Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CEO INTERVIEW: DENIS BURGER - AVI BIOPHARMA INC (AVII).


(PAL228) DENIS BURGER - AVI BIOPHARMA INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic.

Antonym: dec.
 (AVII). Describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward. Sector: Biotechnology. Published date 6/2/02. Tickers featured: AVII. Complete text approximately 3000 words. Document # PAL228.

CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7433. Fax: (212) 668-9842. E-mail: transcript@twst.com.

***
COPYRIGHT 2002 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:CEO INTERVIEW: DENIS BURGER - AVI BIOPHARMA INC (AVII).(Brief Article)
Publication:Wall Street Transcript Digest
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 10, 2002
Words:89
Previous Article:CEO INTERVIEW: LEONARD KRUIMER - CRUCELL NV (CRXL).
Next Article:[0] CEO INTERVIEW: UNA RYAN - AVANT IMMUNOTHERAPEUTICS INC (AVAN).
Topics:



Related Articles
AVI BIOPHARMA STARTS DEVELOPMENT OF TWO CANCER ANTIBODIES.
AVI BIOPHARMA/GENE TOOLS EXPAND LICENSE PACT.
AVI'S NEUGEN SHOWN TO BE POTENT ANTI-CANCER AGENT.
Medtronic to Webcast Vascular Business Update from Paris Course on Revascularization; Presentation Will Also Highlight Exclusive Agreement with AVI...
AVI BioPharma's CEO to Present Company Milestones at UBS Warburg Global Life Sciences Conference.
CEO INTERVIEW: DENIS BURGER - AVI BIOPHARMA INC (AVII).
CEO INTERVIEW: DENIS BURGER - AVI BIOPHARMA INC (AVII).
AVI BIOPHARMA INITIATES PHASE II CARDIOVASCULAR CLINICAL STUDY.
AVI BIOPHARMA MODIFIES HEPATITIS C VIRUS CLINICAL STUDY.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles